Sign In
Buy FBRX
$43.92
+7.22 (+19.67%)
At Close: Jul 10, 2026
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
03:02pm, Thursday, 09'th Jul 2026
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
Forte Biosciences shares surge after positive phase 1b vitiligo results
01:30pm, Thursday, 09'th Jul 2026
Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational therapy for vitiligo, showing statistically si
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study
12:26pm, Thursday, 09'th Jul 2026
Read Also: Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
Forte Biosciences shares surge after positive phase 1b vitiligo results
09:26am, Thursday, 09'th Jul 2026
Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational...
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
09:00am, Thursday, 09'th Jul 2026
Forte Biosciences, Inc. ([url="]www.fortebiorx.com[/url]) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-relat
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
08:00am, Thursday, 09'th Jul 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Monday, 11'th May 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
09:01am, Monday, 11'th May 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts
02:15pm, Friday, 10'th Apr 2026
Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically signi
Forte Biosciences Announces Pricing of $150 Million Public Offering
09:30pm, Wednesday, 08'th Apr 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ
Forte Biosciences Announces Proposed Public Offering
04:02pm, Wednesday, 08'th Apr 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
01:09am, Thursday, 02'nd Apr 2026
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the target of some unusual options trading on Wednesday. Investors purchased 30,205 call options on the stock. This represents an increase
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
04:01pm, Tuesday, 31'st Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:01pm, Tuesday, 17'th Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
04:01pm, Wednesday, 04'th Mar 2026
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
